Clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy

Current effective version

PDF iconRevision 1 - Adopted guideline

Reference numberCPMP/EWP/555/95 Rev. 1
Published21/03/2007
Effective from01/10/2007
KeywordsGrowth factors, myelosuppressive therapy, myeloablative therapy
DescriptionThis document provides guidance for the evaluation of products used to reduce the risk of infection, caused by neutropenia induced by cytotoxic chemotherapy or by myeloablative therapy preceding bone marrow transplantation.


Document history

Revision 1

Current version

PDF iconAdopted guideline


PDF iconOverview of comments


PDF iconDraft guideline

In operation: 01/10/2007–present


Published: 21/03/2007


Published: 27/04/2006


Related content


How useful was this page?

Add your rating